NGNE
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Neurogene reported positive long-term Phase 1/2 data for NGN-401 gene therapy in Rett syndromeJun 29, 2026
- Neurogene reports positive interim data in pediatric cohort from NGN-401 gene therapy trial for Rett syndromeNov 13, 2025
- Neurogene announces first participant dosed in Embolden™ registrational trial of NGN-401 gene therapy for Rett syndromeNov 6, 2025
- Neurogene announces positive regulatory update for NGN-401 gene therapy in Rett syndrome with plans to initiate dosing in Embolden™ registrational trial in Q4 2025Oct 9, 2025
- Neurogene announces registrational trial design for Embolden™ study of NGN-401 gene therapy in Rett syndromeJul 1, 2025